Exabis Library
Welcome to the e-CCO Library!
P401: Confocal laser endomicroscopy predicts response in patients with acute inflammatory bowel disease undergoing anti-integrin therapy with vedolizumab
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P401: Reduction of dosing intervals is the preferable dose optimisation strategy for infliximab to suppress formation of anti-drug antibodies
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P401: Risk of severe COVID-19 outcomes associated with inflammatory bowel disease medications: Reassuring insights from the United Kingdom PREPARE-IBD multicentre cohort study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P401: Tofacitinib tissue exposure correlates with endoscopic outcome
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P402 Prediction of emergency department re-visit among Crohn’s disease patients: a retrospective study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P402: A novel high-dose mesalazine tablet is as effective as conventional low-dose mesalazine tablets in inducing remission in patients with mildly to moderately active ulcerative colitis (UC): A double-blind, double-dummy, multicentre, randomised trial
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P402: A Pilot Study on the Effect of Colesevelam on the Microbiome in Primary Terminal Ileal Resected Crohn's Disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P402: Discontinuation of short-term infliximab maintenance therapy in patients with Crohn's disease: outcomes and risk factors associated with relapse
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P402: Incidence and outcomes of herpes zoster in the ozanimod phase 3 ulcerative colitis and relapsing multiple sclerosis clinical program
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P402: Interstitial and granulomatous lung disease in inflammatory bowel disease patients
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P402: Is co-trimoxazole prophylaxis necessary for Inflammatory Bowel Disease patients receiving triple immunosuppression?
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P402: Systemic steroids vs. local acting steroids: Relative risk for corticosteroid-related adverse events
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P403 Post hoc examination of VISIBLE 1 data for baseline predictors of response to 2 or 3 IV doses of vedolizumab for adults with moderate-to-severe ulcerative colitis
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P403: Adherence to vaccination recommendations in patients with Inflammatory Bowel Disease: a long way for improving.
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P403: Combined therapy with anti-TNF and immunomodulator is superior to monotherapy for postoperative prophylaxis in Crohn’s disease after intestinal resection: a retrospective analysis from a tertiary centre
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P403: Golimumab therapy for ulcerative colitis – an Irish multicentre experience
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P403: Intravenous iron infusion in inflammatory bowel disease: efficacy and ferro-economics
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P403: The role of Organic Cation Transporter (OCTN)-1 in predicting individual response to therapy in Ulcerative Colitis: towards a personalized approach.
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P403: Therapeutic compliance in patients with chronic inflammatory bowel disease.
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P403: Treatment naïve newly diagnosed patients with Crohn's disease have microbial dysbiosis correlated with disease activity and faecal calprotectin—results from a prospective inception cohort
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM